Kamath's GLP-1 Surprise Post Misleads Without India Qualifier

Nithin Kamath's claim that GLP-1 sales haven't picked up ignores record global demand for Ozempic and Wegovy; statement only holds if limited to India's cost- and access-constrained market.

bt-corporate · 6/28/2026, 2:53:10 PM · Ask about this →